Related Experiment Video
Updated: Nov 26, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates
Xiaolong He1,2, Jie Gao1,2, Liang Peng3
1Department of Infectious Disease, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, China.
Objective:
O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation. Gut microbiota encode various enzymes involved in O-GlcNAcylation. However, the characteristics, abundance and function of these enzymes are unknown.
Design:
We first investigated the structure and taxonomic distribution of bacterial OGAs and OGTs. Then, we performed metagenomic analysis to explore the OGA genes abundance in health samples and different diseases. Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
Results:
We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut. Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs. A pooled analysis on 1999 metagenomic samples encompassed six diseases revealed that bacterial OGA genes were conserved in healthy human gut with high abundance, and reduced exclusively in ulcerative colitis. In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling. In vivo studies demonstrated that gut bacteria-derived OGAs could protect mice from chemically induced colonic inflammation through hydrolysing O-GlcNAcylated proteins.
Conclusion:
Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
Insights
Gut bacteria possess O-linked N-acetylglucosaminidase (OGA) enzymes that reduce gut inflammation by modifying host proteins. These bacterial OGA genes are abundant in healthy guts but decreased in ulcerative colitis.
Area of Science:
- Microbiology
- Molecular Biology
- Immunology
Background:
- O-linked N-acetylglucosaminylation (O-GlcNAcylation) is a critical post-translational modification regulating gut inflammation.
- Gut microbiota contain enzymes involved in O-GlcNAcylation, but their roles remain largely uncharacterized.
Purpose of the Study:
- To investigate the characteristics, abundance, and function of bacterial enzymes involved in O-GlcNAcylation, specifically O-linked N-acetylglucosaminidases (OGAs) and O-GlcNAc transferases (OGTs).
- To determine the impact of bacterial OGAs on host cell protein modification and gut inflammatory responses.
Main Methods:
- Taxonomic distribution and structural analysis of bacterial OGAs and OGTs.
- Metagenomic analysis of OGA gene abundance in healthy and diseased human gut samples.
- In vitro and in vivo experiments to assess the enzymatic activity and anti-inflammatory effects of bacterial OGAs.
Main Results:
- Bacterial OGAs, not OGTs, are enriched in major gut phyla (Bacteroidetes, Firmicutes) and often secreted with conserved catalytic domains.
- Bacterial OGA genes are abundant in healthy guts but significantly reduced in ulcerative colitis patients.
- Bacterial OGAs hydrolyze host O-GlcNAcylated proteins, including NF-κB-p65, and protect against chemically induced colonic inflammation in mice.
Conclusions:
- Gut microbiota-derived OGAs possess enzymatic activity that influences intestinal physiology.
- Bacterial OGAs represent a potential therapeutic target for managing colonic inflammation.
More Related Videos
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

